- TRUE HUMAN™
- CORPORATE STRATEGY
Vascular disease is by far the largest unmet medical need in the industrialized world. Annual costs in the U.S. alone are about US$450 billion, according to the American Heart Association. To date, there has been very little development for therapeutic antibodies in this sector. Our current clinical trials are aimed at demonstrating MABp1 treatment benefit when given contemporaneously and subsequent to revascularization procedures (i.e. stent placement in an artery). We believe, however, that successful results in these trials will demonstrate a wider utility for our antibody in broad areas of vascular disease.
As previously demonstrated by other antibody products, being the first antibody therapy in a sector can have an important impact on market staying power. If XBiotech can achieve first-to-market status for its anti-vascular disease treatment, the potential market success for this product could be very substantial. The recent clinical results, showing reduced Major Adverse Cardiac Events (MACE) in patients treated with vascular disease is very encouraging.
© 2012 XBiotech USA, Inc. | All Rights Reserved